一、个人简介

邱立朋，博士、副教授、硕士生导师。沈阳药科大学药剂学博士学位，山东大学/翔宇药业股份有限公司博士后，牛津大学访问学者。江苏省药学会海洋药物专委会委员，江苏省预防医学会全球卫生专委会委员，中国药学会高级会员，沈阳药科大学学报首届青年编委，The second Youth Editorial Board Member of Asian Journal of Pharmaceutical Sciences，Youth Editorial Board Member of Biomaterials Translational，Youth Editorial Board Member of Nano TransMed。

二、研究领域

纳米药物递送系统；生物药物新剂型；中药创新制剂；功能食品/医美新剂型

三、荣誉奖励

全国大学生挑战杯优秀指导教师

江南大学“青年至善学者”

江南大学教学成果特等奖

江南大学优秀毕业论文指导教师

高等学校科学研究技术进步二等奖

中国商业联合会科技进步一等奖

四、学术成果

（一）代表性项目

主持科技部重点研发计划项目子课题、国家自然科学基金青年项目、中国博士后科学基金面上（一等资助）项目、江苏省自然科学基金面上项目、山东省博士后创新项目等国家和省部级课题；负责开展新型小分子化合物可开发性研究、透明质酸冻干制剂的研发、延胡索乙素纳米微乳的研制、肠道癌前病变防控体系的建立与应用等校企合作研究课题。

（二）代表性论文

多年来，围绕多糖生物载体材料合成、智能药物递送系统构建、细胞和动物作用评价等进行研究，以一作/通讯作者在专业期刊发表论文60余篇，其中，SCI论文40余篇，累积引用超过2400次，H指数23。主要代表作如下：

[1] Enhanced Effect of pH-Sensitive Mixed Copolymer Micelles for Overcoming Multidrug Resistance of Doxorubicin. Biomaterials. 2014, 35(37): 9877-9887.

[2] Self-assembled pH-responsive Hyaluronic Acid-g-poly (L-histidine) Copolymer Micelles for Targeted Intracellular Delivery of Doxorubicin. Acta Biomaterialia. 2014, 10 (5): 2024-2035.

[3] cRGDyK modified pH responsive nanoparticles for specific intracellular delivery of doxorubicin. Acta Biomaterialia. 2016, 30: 285-298.

[4] pH-Sensitive degradable polymeric micelles for bio-triggered targeted anti-tumor drug delivery, J Control Release. 2017, 259: e86-e87.

[5] pH-triggered degradable polymeric micelles for targeted anti-tumor drug delivery. Mater Sci Eng C Mater Biol Appl. 2017, 78: 912-922.

[6] Designing heparan sulfate-based biocompatible polymers and their application for intracellular stimuli-sensitive drug delivery. Mater Sci Eng C Mater Biol Appl. 2019, 94: 465-476.

[7] Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect. Mater Sci Eng C Mater Biol Appl. 2019, 99:1448-1458.

[8] Elucidation of cellular uptake and intracellular trafficking of heparosan polysaccharide-based micelles in various cancer cells. Int J Biol Macromol. 2019, 130:755-764.

[9] Redox-responsive biocompatible nanocarriers based on novel heparosan polysaccharides for intracellular anticancer drug delivery. Asian J Pharm Sci. 2020, 15(1): 83-94.

[10] A facile synthesis of uniform hollow MIL-125 titanium-based nanoplatform for endosomal esacpe and intracellular drug delivery. Chem Eng J, 2020, 396: 125246.

[11] Bacteria-mediated cancer therapies: opportunities and challenges. Biomater Sci. 2021, 9(17): 5732-5744.

[12] Biological role of heparan sulfate in osteogenesis: A review. Carbohydr Polym. 2021, 272: 118490.

[13] Carbon Nitride Nanosheets for Imaging Traceable CpG Oligodeoxynucleotide Delivery. ACS Appl Nano Mater, 2021, 4(8): 8546-8555.

[14] Stimuli-responsive, dual-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance. Acta Biomater. 2021, 140:686-699.

[15] Dexamethasone microspheres and celecoxib microcrystals loaded into injectable gels for enhanced knee osteoarthritis therapy. Int J Pharm, 2022, 622, 121802.

[16] Enzyme-loaded glycogen nanoparticles with tumor-targeting Activatable host-guest supramolecule for augmented chemodynamic therapy. Int J Biol Macromol, 2022, 217: 878-889.

[17] Engineered bacteria combined with doxorubicin nanoparticles suppress angiogenesis and metastasis in murine melanoma models. Acta Biomater, 2023, 158:734-746.

[18] Oral delivery of layer-by-layer coated exosomes for colitis therapy. J Control Release, 2023, 354:635-650.

[19] Tumor-targeted glycogen nanoparticles loaded with hemin and glucose oxidase to promote tumor synergistic therapy. Int J Biol Macromol, 2023, 239:124363.

[20] A Purposefully Designed pH/GSH-Responsive MnFe-Based Metal-Organic Frameworks as Cascade Nanoreactor for Enhanced Chemo-Chemodynamic-Starvation Synergistic Therapy. Small. 2023: e2303403.

[21] Aminated yeast β-D-glucan for macrophage-targeted delivery of CpG oligodeoxynucleotides and synergistically enhanced cancer immunotherapy. Int J Biol Macromol, 2023, 253(Pt 3):126998.

[22] Nanoparticle/Engineered Bacteria Based Triple-Strategy Delivery System for Enhanced Hepatocellular Carcinoma Cancer Therapy. Int J Nanomedicine. 2024, 19:3827-3846.

[23] A Novel CaCu-Metal-Organic-Framework Based Multimodal Treatment Platform for Enhanced Synergistic Therapy of Hepatocellular Carcinoma. Adv Healthc Mater. 2024, 13(17):e2304000.

（三）国家发明专利

[1]一种注射用多功能复合型水凝胶及其制备方法，201810185988.1

[2]一种塞来昔布微晶、负载塞来昔布微晶的温敏性凝胶及其制备方法，202110773477.3

[3]伊曲康唑缓释微球的制备及应用，2022111974632

[4]一种壳聚糖缩硫酮活性氧清除水凝胶的制备方法和产品及应用，2023111165473

[5]一种塞来昔布聚合物前药的制备方法及应用，2023117556752

[6]一种口服递药系统及其在蛋白多肽类药物递送领域的应用，2024114584971

五、联系方式

通讯地址：江苏省无锡市蠡湖大道1800号江南大学生命科学与健康工程学院

邮编：214122

邮箱：qiulp@jiangnan.edu.cn

【以上资料更新日期】：2025年3月